Federal contract award
75A50122C00076
THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $110.9M |
| Current contract value | $110.9M |
| Potential contract value / ceiling | $299.0M |
| Start date | Sep 28, 2022 |
| Current end date | May 1, 2031 |
| Potential end date | Jul 31, 2036 |
| Latest award activity | Jul 13, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 18 of 18 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 13, 2026 | P00017 | $0 | 75A50122C00076 TRANSFERS THE PROPERTY LISTED WITHIN THE MODIFICATION TO MEDICAL CBRN DEFENSE CONSORTIUM (MCDC) BASE AGREEMENT NO. 2018-843, PROJECT AGREEMENT NO. 1 TO SUPPORT ANALYSIS OF GLYCOPROTEIN VARIANTS IN THE VSV-MARV-GP NEUTRALIZATION ASSAY F |
| May 14, 2026 | P00016 | $0 | RECEIVE PROPERTY TRANSFERRED FROM HHSO100201900018C. |
| Feb 20, 2026 | P00015 | $0 | TRANSFER PROPERTY TO HHSO100201600021C. |
| Aug 25, 2025 | P00014 | $0 | RECEIVE PROPERTY TRANSFER. |
| Jul 7, 2025 | P00013 | $0 | UPDATE COR TO SAIMA ZAMAN AND ALT-COR TO CAROL DIAZ-DIAZ. |
| May 7, 2025 | P00012 | $0 | UPDATE G.7 INDIRECT RATES OF CONTRACT NO. 75A50122C00076. |
| Mar 28, 2025 | P00011 | $0 | CONTRACT NO. 75A50122C00076 SHALL TRANSFER GOVERNMENT FURNISHED PROPERTY (GFP) TO CONTRACT NO. 75A50124C00003. |
| Feb 28, 2025 | P00010 | $0 | THIS MOD UPDATES THE COR TO CAROL DIAZ-DIAZ AND REASSIGNS SAIMA ZAMAN AS THE ALT-COR. |
| Jan 30, 2025 | P00009 | $0 | THIS MOD UPDATES THE COR TO CAROL DIAZ-DIAZ AND REASSIGNS SAIMA ZAMAN AS THE ALT-COR. |
| Dec 13, 2024 | P00008 | $0 | THIS MOD TRANSFERS GFP BETWEEN CONTRACTS. |
| Nov 15, 2024 | P00007 | $0 | THIS MOD TRANSFERS GFP BETWEEN CONTRACTS. |
| Sep 24, 2024 | P00006 | $0 | THIS MOD TRANSFERS GFP BETWEEN CONTRACTS. |
| May 21, 2024 | P00005 | $0 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
| Mar 8, 2024 | P00004 | $0 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
| Aug 7, 2023 | P00003 | $12.6M | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
| Apr 19, 2023 | P00002 | $19.8M | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
| Feb 10, 2023 | P00001 | $0 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
| Sep 28, 2022 | 0 | $78.5M | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. |
Estimated positioning window
Jul 31, 2035 – Jan 31, 2036
Recompete signal: . Rule-based research score; positioning dates are estimates.
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2036-07-31 (3567 days from calculation)
- +5 points
- 121 historical awards in this buyer and category group
- +15 points
- 18 recorded award transactions
- +10 points
- Latest award action: 2026-07-13
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.